Intellia's gene-editing ATTR treatment cuts abnormal proteins in monkeys

CRISPR technology for genome editing (Source: AstraZeneca)
So far, one dose of Intellia's gene-editing treatment kept circulating TTR protein levels down in monkeys for more than six months. (AstraZeneca)

Until this year, there were no treatments for transthyretin amyloidosis, a rare disease where misfolding transthyretin (TTR) proteins build up in the body’s tissues. Then, in quick succession, the FDA approved a pair of drugs that interfere with RNA to block the production of these proteins. Another drug in the pipeline works similarly, by stabilizing TTR and stopping it from folding incorrectly.

Intellia Therapeutics wants to intervene earlier, using a CRISPR-based treatment to edit the mutation underlying the disease. The company presented (PDF) preclinical data Thursday at the annual meeting of the European Society of Gene and Cell Therapy showing that delivering a CRISPR-Cas9 treatment to the liver could potentially reduce TTR levels and treat ATTR. It is partnering with Regeneron on the treatment. 

Transthyretin amyloidosis, or ATTR, is caused by mutations in the TTR gene, which give rise to abnormal TTR proteins. These proteins then collect in aggregates called amyloids, most frequently in the peripheral nervous system, though ATTR can also affect the central nervous system and the heart. Most TTR is made in the liver, making it an attractive target for treatment. 

The nonhuman primate data presented Thursday showed “a high correlation between liver editing and reduction of the transthyretin (TTR) protein,” Intellia said in a statement. Furthermore, the researchers found that a relatively low editing rate of 35% to 40% was needed to “achieve therapeutically meaningful reduction of TTR,” specifically, a drop in TTR protein of more than 60%.

With its liquid nanoparticle delivery, the treatment could be safer than other CRISPR approaches. The data showed both the nanoparticles and their cargo were cleared from the animals’ circulation within five days. This could allay concerns about off-target edits that come with “traditional” CRISPR, which is delivered using viral vectors, typically adeno-associated viruses (AAVs). While AAVs are the most advanced method of CRISPR delivery, they allow the Cas9 enzyme—known as CRISPR “scissors”—to persist in the cells and potentially make unintended edits to the genome after treatment is complete. 


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

RELATED: Alnylam vows value-based pricing, financial help with $450K Onpattro launch 

The Intellia research is ongoing, but so far, one dose of the gene-editing treatment has kept circulating TTR levels down for more than six months. This could be attractive for patients and physicians, as the two approved therapies for ATTR are injected more frequently than that. A physician must administer Alnylam’s Onpattro every three weeks, while Ionis and Akcea’s Tegsedi can be self-injected, albeit more often at once a week. 

Pfizer’s oral drug, tafamidis, seems to be playing catch-up, but it is designed to treat different manifestations of ATTR. While Onpattro and Tegsedi both target polyneuropathy, tafamidis specifically addresses cardiomyopathy. That said, patients often have both symptoms, and so could be treated with either Onpattro or tafamidis, according to Credit Suisse analysts. And physicians may end up using Onpattro off-label “to treat cardiomyopathy while getting reimbursement for polyneuropathy,” the analysts wrote.

Meanwhile, Intellia has big plans for its nanoparticle-based CRISPR system. As its researchers continue to perfect the technology, they hope they are "opening the door for the development of therapies for a wide range of genetic diseases that require stable gene insertion and expression," according to the statement.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.